ARL2 and prostate cancer: Targets glutamate dehydrogenase 1 (GLUD1) and ADPribosylation protein (ARL2) in bladder tumor cells. Suppresses proliferation, migration, invasion, and apoptosis in clear cell renal cell carcinoma cell line. In prostate cancer, inhibits cancer growth and epithelial-mesenchymal transition (EMT).